Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDC's Opioid Final Guideline Narrows Duration Of Use For Chronic Pain

This article was originally published in The Pink Sheet Daily

Executive Summary

Three days of opioid use for acute pain 'will often be sufficient' and more than seven days 'will rarely be needed;' NEJM editorial by CDC officials emphasizes risks of opioid use.

You may also be interested in...

Opana ER Panel Urged To Disregard ‘Invalid’ Human Abuse Liability Study

In unusual public hearing, Edwin Thompson, head of the US firm that contract manufactures Endo’s long-acting opioid, tells US FDA advisory committee that intranasal ‘liking’ study violated FDA requirements. Thompson has petitioned the agency to do away with need for human abuse liability studies entirely, asserting they are inherently flawed.

iPLEDGE REMS: FDA Panel To Consider Changing Pregnancy Testing, Counseling Requirements

Advisory committee to discuss proposed changes to isotretinoin REMS to minimize burden and treatment delays while preventing risk of fetal exposure. Agency recommends against at-home pregnancy tests.

Biopharma Industry Sharply Divided Over Supreme Court Antibody Patent Brawl

Big biologic makers line up on opposite sides of dispute between Amgen and Sanofi over whether Amgen’s Repatha patents cover analogous antibodies with the same functional characteristics.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts